(Q47744808)

5 February 2018

title

Durability of infliximab in Crohn's disease: a single-center experience (English)

1 reference

5 February 2018

1 reference

Ashwin N Ananthakrishnan

2

object named as

Ashwin N Ananthakrishnan

1 reference

5 February 2018

author name string

Jason E Gonzaga

1

1 reference

5 February 2018

Mazen Issa

3

1 reference

5 February 2018

Dawn B Beaulieu

4

1 reference

5 February 2018

Sue Skaros

5

1 reference

5 February 2018

Yelena Zadvornova

6

1 reference

5 February 2018

Kathryn Johnson

7

1 reference

5 February 2018

Mary F Otterson

8

1 reference

5 February 2018

David G Binion

9

1 reference

5 February 2018

publication date

21 May 2009

1 reference

5 February 2018

Inflammatory Bowel Diseases

published in

1 reference

5 February 2018

volume

15

1 reference

5 February 2018

issue

12

1 reference

5 February 2018

page(s)

1837-1843

1 reference

5 February 2018

Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis

cites work

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

Optimizing anti-TNF treatment in inflammatory bowel disease

21 January 2018

1 reference

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

21 January 2018

1 reference

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

Treatment with biologic therapies and the risk of cancer in patients with IBD.

21 January 2018

1 reference

Safety of biologic therapy

21 January 2018

1 reference

Safety of biologics in inflammatory bowel disease

21 January 2018

1 reference

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

21 January 2018

1 reference

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

21 January 2018

1 reference

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center

21 January 2018

1 reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

Predictors of medication adherence in inflammatory bowel disease.

21 January 2018

1 reference

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.20974

1 reference

5 February 2018

1 reference

5 February 2018